Comment from argenx

Summary: Argenx, a pharmaceutical company, provides a series of clarifying questions and requests for further detail regarding the draft guidance on protocol deviations. Their comments focus on the distinction between important and non-important deviations, the classification of eligibility criteria, and the roles of sponsors versus investigators in detecting and reporting deviations.